Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

Completed · Phase 2

Conditions studied: Endometrial Cancer

In brief

RATIONALE: Estrogen can stimulate the growth of endometrial cancer cells. Hormone therapy using raloxifene may fight endometrial cancer by reducing the production of estrogen. PURPOSE: Phase II trial to study the effectiveness of raloxifene in treating patients who have persistent or recurrent endometrial cancer.

Key facts

Study ID

NCT00004915

Run by

Northwestern University

Starts

1998-11-01

Expected to finish

2000-02-01

Last updated by the study team

2012-06-06

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.